Literature DB >> 2068312

Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology.

M W van den Brekel1, J A Castelijns, H V Stel, W J Luth, J Valk, I van der Waal, G B Snow.   

Abstract

The authors performed a prospective study of the value of ultrasonography (US) and US-guided fine-needle aspiration cytology (FNAC) for assessment of N0 lesions in the neck. Preoperative US was performed in 107 patients with squamous cell carcinoma of the head and neck, who underwent 132 elective neck dissections. During the US examination of the last 54 patients, who underwent 70 elective neck dissections, US-guided FNAC was performed. US alone was found to be an unreliable method for detecting occult lymph node metastasis; the accuracy never exceeded 70% (93 of 132), with a sensitivity of 60% (32 of 53) and a specificity of 77% (61 of 79). In contrast, US-guided FNAC had an accuracy of 89% (62 of 70), a sensitivity of 76% (25 of 33), and a specificity of 100% (37 of 37). Because of the high sensitivity and specificity of US-guided FNAC for the assessment of the N0 neck, this modality may play an important role in directing treatment of these patients in the future.

Entities:  

Mesh:

Year:  1991        PMID: 2068312     DOI: 10.1148/radiology.180.2.2068312

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Detection of lymph node metastases in the neck: radiologic criteria.

Authors:  J A Castelijns; M W van den Brekel
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

2.  Combination of helical CT and Doppler sonography in the follow-up of patients with clinical N0 stage neck disease and oral cancer.

Authors:  Sato Eida; Misa Sumi; Koichi Yonetsu; Yasuo Kimura; Takashi Nakamura
Journal:  AJNR Am J Neuroradiol       Date:  2003-03       Impact factor: 3.825

Review 3.  Management of cervical metastasis.

Authors:  Eric J Lentsch
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 4.  Management of cervical lymph nodes in patients with head and neck cancer.

Authors:  G B Snow; P Patel; C R Leemans; R Tiwari
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

5.  Diagnostic accuracy and additional value of diffusion-weighted imaging for discrimination of malignant cervical lymph nodes in head and neck squamous cell carcinoma.

Authors:  R B J de Bondt; M C Hoeberigs; P J Nelemans; W M L L G Deserno; C Peutz-Kootstra; B Kremer; R G H Beets-Tan
Journal:  Neuroradiology       Date:  2009-01-10       Impact factor: 2.804

6.  Comparison of the efficacy of clinical examination, ultrasound neck and computed tomography in detection and staging of cervical lymph node metastasis in head and neck cancers.

Authors:  Nitin Anand; Neena Chaudhary; M K Mittal; Rajni Prasad
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2007-04-26

7.  Comparison of PET/CT with conventional imaging modalities (USG, CECT) in evaluation of N0 neck in head and neck squamous cell carcinoma.

Authors:  Ashutosh Chauhan; Pranjal Kulshrestha; Sanjay Kapoor; Harkirat Singh; M J Jacob; Maneel Patel; Manomoy Ganguly
Journal:  Med J Armed Forces India       Date:  2012-07-17

8.  Reproduction of occult metastasis of head and neck cancer in nude mice.

Authors:  S Kawashiri; S Kumagai; K Kojima; H Harada; K Nakagawa; E Yamamoto
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

9.  Aggressive basal cell carcinoma of the head and neck: challenges in surgical management.

Authors:  Peter J F M Lohuis; Anil Joshi; Pepijn A Borggreven; Lenka Vermeeren; Biljana Zupan-Kajcovski; Abrahim Al-Mamgani; Alfons J M Balm
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-11       Impact factor: 2.503

Review 10.  Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers.

Authors:  Hubert Vermeersch; David Loose; Hamphrey Ham; Andreas Otte; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.